The London and Cambridge Life Sciences team advised MiroBio on the entry into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists.
MiroBio Ltd is a clinical-stage private biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune balance in autoimmune patients.
Gilead Sciences has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
The Goodwin team was led by Elizabeth Rhodes and Graham Defries with support from Kesten Laverty, Richard Bloomfield, Kenny Walker-Durrant and Olivia Armstrong (Corporate), Robert Young and Satvi Vepa (Tax) and Tim Worden and Lucy Sharples (IP).
For more information please see here.